Core Insights - Tectonic Therapeutic, Inc. announced positive topline results from the Phase 1b Part B clinical trial of TX45, showing significant improvements in left heart function and pulmonary hemodynamics in patients with Group 2 PH-HFrEF [1][4][8] Clinical Trial Overview - The Phase 1b Part B trial evaluated TX45 in an expanded patient population of Group 2 PH-HFrEF, building on previous positive results from the Phase 1b Part A trial in Group 2 PH-HFpEF [2][3] - The ongoing APEX Phase 2 clinical trial aims to assess TX45 over a 24-week treatment period in patients with PH-HFpEF, with topline results expected in 2026 [2] Hemodynamic Results - TX45 administration led to meaningful improvements in hemodynamic measures, including a 29.2% reduction in pulmonary capillary wedge pressure (PCWP) and a 17.3% increase in cardiac output (CO) [7][9] - Other significant changes included a 19.3% decrease in mean pulmonary artery pressure (mPAP) and a 29.2% reduction in total pulmonary resistance (TPR) [9] Safety and Tolerability - TX45 was well tolerated among patients with no serious or severe adverse events reported, and no clinically significant changes in blood pressure or immune-related reactions were observed [8][11] Echocardiography Results - Echocardiography data indicated persistent improvements in left and right ventricular function and pulmonary hemodynamics at 29 days post-dose [10][12] Future Directions - The results from the Phase 1b Part B trial open the potential for TX45 to address significant unmet needs in the PH-HFrEF patient population, pending further results from the APEX Phase 2 trial [3][12]
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF